Raymond James analyst Steven Seedhouse raised the firm’s price target on Zura Bio to $22 from $20 and keeps a Strong Buy rating on the shares following the Q2 earnings. Zura plans to initiate Phase 2 studies evaluating lead asset ZB-106 in hidradenitis suppurativa and systemic sclerosis by 2H24, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZURA: